We've detected that Javascript is not enabled. It is required for an optimal survey taking experience.
Please check your browser's settings and make sure Javascript is turned on. Learn how to enable Javascript.

Skip survey header

MASH Product Theater Program Evaluation SBHPP, October 20, 2025

1. I am a(n):

Please enter an 'other' value for this selection.

2. My specialty is:

PRESENTATION

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.

3. The speaker was knowledgeable about the content. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

4. The speaker was engaging and delivered the presentation clearly and effectively. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

5. The information presented on the slides was clear and easy to understand.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

ACTIONS

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.

6. As a result of this program, I intend to:
Consider this medication as a treatment option for appropriate patients with MASH. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

7. As a result of this program, I intend to:
Initiate this treatment in appropriate patients with MASH. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

OBJECTIVES

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.

8. As a result of this program, I am better able to:
Understand the epidemiology and disease burden of MASH, as well as the current guidelines for screening. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

9. As a result of this program, I am better able to:
Examine the efficacy and safety data for semaglutide in appropriate patients with MASH. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

10. As a result of this program, I am better able to:
Understand the dosing and administration of this product for appropriate patients with MASH. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

OVERALL

1=Strongly Disagree, 4=Neutral, 7=Strongly Agree.
* Required Field.

11. My interest in learning about this topic and/or other topics related to it has increased as a result of attending this program. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

12. I will apply and incorporate what I learned from this program into my own practice. *This question is required.

1	2	3	4	5	6	7	Not applicable
1	2	3	4	5	6	7	Not applicable

INTEREST
Please mark accordingly:

13. I am interested in receiving educational resources about MASH and use of this product for appropriate patients with MASH. *This question is required.

Please enter an 'other' value for this selection.

Opt In for Additional MASLD/MASH Resources *This question is required.

I agree and certify I am at least eighteen (18) years of age.

By providing my consent to Novo Nordisk, I certify that I am a US healthcare professional, and agree to the collection, use, and disclosure of my personal information to receive information related to specific products, services, or diseases. I also understand that I may opt out from receiving any future communications from Novo Nordisk by clicking the “unsubscribe” link within any email I receive, by calling 1.877.744.2579, or by sending a letter containing my full contact information (eg, name, email address, and phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey, 08536. Novo Nordisk respects the importance of your privacy and will take appropriate measures to protect your information.

14. Do you have any additional feedback you would like to share?